L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemiaopen access
- Authors
- Jung, KS[Jung, Ki Sun]; Cho, SH[Cho, Su-Hee]; Kim, SJ[Kim, Seok Jin]; Ko, YH[Ko, Young Hyeh]; Kang, ES[Kang, Eun-Suk]; Kim, WS[Kim, Won Seog]
- Issue Date
- 18-Apr-2016
- Publisher
- BIOMED CENTRAL LTD
- Keywords
- ANKL; L-asparaginase; Allogeneic HSCT; Response; Survival
- Citation
- JOURNAL OF HEMATOLOGY & ONCOLOGY, v.9, no.1
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF HEMATOLOGY & ONCOLOGY
- Volume
- 9
- Number
- 1
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/36979
- DOI
- 10.1186/s13045-016-0271-4
- ISSN
- 1756-8722
- Abstract
- Aggressive nature killer cell leukemia (ANKL) is a mature NK-T cell lymphoma with worse prognosis, but optimal treatment is unclear. Therefore, we analyzed the efficacy of L-asparaginase-based regimens for ANKL patients. Twenty-one patients who received dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) or etoposide, ifosfamide, dexamethasone, and L-asparaginase (VIDL) chemotherapy at Samsung Medical Center were selected. The overall response rate for all patients was 33 % (7/21); 38 % (5/13) in SMILE and 40 % (2/5) in VIDL, respectively. The median progression-free survival was 3.9 months (95 % CI 0.0-8.1 months) and median overall survival was 7.0 months (95 % CI 2.3-11.7 months). Treatment response (P = 0.001), hematopoietic stem cell transplantation (HSCT) (P = 0.007) and negative conversion of Epstein-Barr virus (EBV) DNA titer after treatment (P = 0.004) were significantly associated with survival. Thus, L-asparaginase-based regimens followed by allogeneic HSCT seem to improve the outcome for ANKL patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.